ZYVERSA THERAPEUTICS, INC. — Income Charts
12 quarters of history · ending 2025-09-30 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$-131K
R&D↑+201.1% +$244K
$365K
D&A↓-100.0% -$3K
$0
Operating Income
$-21M
EBITDA
$-21M
Interest Income
—
Other Income/Expense
$95K
Pretax Income
$-21M
Tax Provision
$-852K
Net Income
$-20M
Operating Margin
15799.1%
Net Margin
15078.5%
Effective Tax Rate
4.1%
Deferred Tax Liabilities↓-100.0% -$10K
$0
ETR (Continuing Operations)↓-8.9pts
-0.1%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-0.8pts
3.0%
Pension Net Periodic Cost
$37K
Revenue YoY Variation↓-224181.5pts
-224100.0%
Income YoY Variation↓-71.0pts
25.8%
Revenue QoQ Variation↓-51.3pts
-8.8%
Income QoQ Variation↑+2.1pts
4.7%